| 03 Dec 2010 |
INTUNIV™ - Shire Files Suit against Impax and Watson |
| 01 Dec 2010 |
VPRIVMC (vélaglucérase alfa) est approuvé au Canada pour le traitement de la maladie de Gaucher de type 1 |
| 01 Dec 2010 |
Total Voting Rights |
| 01 Dec 2010 |
Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR® (icatibant) for Acute Attacks of Hereditary Angioedema |
| 01 Dec 2010 |
VPRIV® (velaglucerase alfa) Approved in Canada for the Treatment of Type I Gaucher Disease |
| 23 Nov 2010 |
Block listing six monthly return (25KB PDF) |
| 15 Nov 2010 |
FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents |
| 10 Nov 2010 |
Five-Year Market Exclusivity for VYVANSE® Upheld |
| 09 Nov 2010 |
Shire finalises its acquisition of Movetis NV following completion of the Squeeze-Out Process |
| 04 Nov 2010 |
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease |
| 02 Nov 2010 |
Directors/PDMR Shareholding |
| 01 Nov 2010 |
Total Voting Rights |
| 01 Nov 2010 |
Shire Receives INTUNIV™ Paragraph IV Notice Letter |
| 29 Oct 2010 |
Continued excellent performance in Q3. Full year earnings expectations increased. New value in pipeline emerging |
| 29 Oct 2010 |
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder |
| 28 Oct 2010 |
Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments |
| 26 Oct 2010 |
Shire Receives INTUNIV™ Paragraph IV Notice Letter |
| 18 Oct 2010 |
Third quarter 2010 results date notification - October 29, 2010 |
| 13 Oct 2010 |
Shire Acquires 99.21% of the shares of Movetis N.V. and Announces Commencement of Squeeze-Out Tender Period |
| 11 Oct 2010 |
Shire Appoints Philip J. Vickers, PhD as Senior Vice President of Research & Development for Human Genetic Therapies Business |
| 01 Oct 2010 |
Total Voting Rights |
| 30 Sep 2010 |
Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period |
| 16 Sep 2010 |
“Fact or Fiction: ADHD in America, a Capitol Hill Forum” |
| 13 Sep 2010 |
Shire Update on ProAmatine® (midodrine HCl) |
| 09 Sep 2010 |
Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma |
| 06 Sep 2010 |
Shire Announces Commencement of Tender Offer to Acquire Movetis NV |
| 01 Sep 2010 |
Elections for Interim Dividend in Respect of the Six Months to June 30, 2010 |
| 01 Sep 2010 |
Total Voting Rights |
| 31 Aug 2010 |
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide |
| 26 Aug 2010 |
Shire Announces European Approval of VPRIV® (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease |
| 26 Aug 2010 |
Notification of major interests in shares (28KB PDF) |
| 24 Aug 2010 |
Pentasa® - Shire Receives Ruling From FDA on Citizen’s Petition |
| 20 Aug 2010 |
Correction - Director/PDMR Shareholding |
| 17 Aug 2010 |
Statement re ProAmatine |
| 17 Aug 2010 |
Director/PDMR Shareholding |
| 11 Aug 2010 |
Half Yearly Report |
| 10 Aug 2010 |
Shire agrees to divest Daytrana® (methylphenidate transdermal system) CII to Noven Pharmaceuticals, Inc.; Shire’s 2010 earnings outlook unchanged |
| 05 Aug 2010 |
Director/PDMR Shareholding |
| 05 Aug 2010 |
Published Study Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Provided Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD |
| 04 Aug 2010 |
Study Published in the New England Journal of Medicine Demonstrates Efficacy and Favourable Safety Profile of Firazyr® (Icatibant) for the Treatment of Hereditary Angioedema (HAE) Attacks |
| 04 Aug 2010 |
Shire delivers excellent Q2 performance with total revenues up 35%. Full year earnings expectations raised. |
| 03 Aug 2010 |
Shire Proposes to Expand Specialist Gastrointestinal Portfolio |
| 02 Aug 2010 |
Shire Appoints Gráinne Higgins Global Vice President of Human Resources for Human Genetic Therapies Business |
| 02 Aug 2010 |
Total Voting Rights |
| 20 Jul 2010 |
Nonsafety voluntary recall and withdrawal of a limited portion of Daytrana® (methylphenidate transdermal system) patches (83KB PDF) |
| 15 Jul 2010 |
Second quarter 2010 results date notification – August 4, 2010 |
| 08 Jul 2010 |
Lialda® - Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc. |
| 06 Jul 2010 |
FDA Approves Daytrana® (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents |
| 01 Jul 2010 |
Total Voting Rights |
| 01 Jul 2010 |
Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV® (velaglucerase alfa) through 69 months |
| 30 Jun 2010 |
Shire Purchases Strategic Site in Massachusetts |
| 28 Jun 2010 |
Shire named Company of the Year at Mediscience Awards |
| 25 Jun 2010 |
Shire Receives CHMP Positive Opinion for VPRIV™ (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union |
| 21 Jun 2010 |
Director/PDMR Shareholding |
| 17 Jun 2010 |
Two New Board Directors Appointed |
| 28 May 2010 |
Shire Receives LIALDA® Paragraph IV Notice Letter from Zydus Pharmaceuticals |
| 25 May 2010 |
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD |
| 19 May 2010 |
Shire Receives 2010 Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for injection) |
| 04 May 2010 |
Total Voting Rights |
| 04 May 2010 |
FDA Approves Labeling Change for Vyvanse® (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD1 |
| 29 Apr 2010 |
Shire's replenished portfolio drives excellent quarterly performance |
| 27 Apr 2010 |
Results of the Annual General Meeting held on April 27, 2010 (19KB PDF) |
| 20 Apr 2010 |
First quarter 2010 results date notification – April 29, 2010 |
| 01 Apr 2010 |
Total Voting Rights |
| 01 Apr 2010 |
Director/PDMR Shareholding |
| 01 Apr 2010 |
Annual Information Update |
| 25 Mar 2010 |
Annual Report and Accounts |
| 25 Mar 2010 |
Shire Presents Positive Data for Patients with Type 1 Gaucher Disease Who Switched to VPRIVTM |
| 18 Mar 2010 |
Director/PDMR Shareholding |
| 15 Mar 2010 |
New Board Director Appointed |
| 11 Mar 2010 |
Director/PDMR Shareholding |
| 09 Mar 2010 |
Director/PDMR Shareholding |
| 05 Mar 2010 |
Director/PDMR Shareholding |
| 04 Mar 2010 |
District Court Upholds FDA’s Grant of 5-Year Market Exclusivity to VYVANSE® |
| 03 Mar 2010 |
Director/PDMR Shareholding |
| 03 Mar 2010 |
Director/PDMR Shareholding |
| 02 Mar 2010 |
Supplementary Reporting Announcement |
| 01 Mar 2010 |
Elections for Interim Dividend in Respect of the Six Months to December 31, 2009 |
| 01 Mar 2010 |
Total Voting Rights |
| 01 Mar 2010 |
March is Kidney Health Month |
| 01 Mar 2010 |
Mars est le mois de la santé rénale |
| 26 Feb 2010 |
Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease |
| 26 Feb 2010 |
FDA Press Release - FDA Approves Therapy to Treat Gaucher Disease |
| 26 Feb 2010 |
Shire Supports Rare Disease Day 2010 |
| 24 Feb 2010 |
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) |
| 19 Feb 2010 |
Excellent results in a transformational year for Shire; core product sales up 25% |
| 11 Feb 2010 |
Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naïve Patients with Type 1 Gaucher Disease |
| 04 Feb 2010 |
Full Year 2009 results date notification – 19 February 2010 |
| 03 Feb 2010 |
Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lysosomal Disease Network (LDN) World Symposium |
| 01 Feb 2010 |
VYVANSE® — new ADHD treatment option — now available in Canada |
| 01 Feb 2010 |
Total Voting Rights |
| 26 Jan 2010 |
Notification of major interests in shares |
| 18 Jan 2010 |
Directorate Change |
| 04 Jan 2010 |
Total Voting Rights |
